Posttransplant toxicity and complications (N = 35)
| Posttransplant outcome . | Value . |
|---|---|
| Follow-up, median (range), y | 5.4 (0.3-10.4) |
| Outpatient allograft infusion | 35 (100) |
| Admission within 100 d | 22 (63) |
| Hospital stay, median (range), d* | 4 (1-74) |
| Cause of admission*(n = 22) | |
| Neutropenic fever | 3 |
| Non-neutropenic fever | 6 |
| Central catheter–related infection | 4 |
| Serum sickness | 3 |
| Others† | 6 |
| Post-HCT cytopenias in first 100 d | |
| Patients with neutrophil nadir <0.5 × 109/L | 6 (17) |
| Patients with platelet nadir <10 × 109/L | 2 (6) |
| Patients with no blood product transfusions | 16 (46) |
| Posttransplant PRBC transfusions, median (range) | 3 (1-35) |
| CMV in first 100 d, n | |
| Reactivation (viremia only)‡ | 17 (49) |
| Organ disease | 0 (0) |
| EBV reactivation§ | 10 (29) |
| Cause of death (n = 17) | |
| Disease progression/relapse | 12 |
| Acute GVHD | 1 |
| Chronic GVHD | 1 |
| Secondary malignancy | 1 |
| Hepatitis | 1 |
| Hemorrhage | 1 |
| Posttransplant outcome . | Value . |
|---|---|
| Follow-up, median (range), y | 5.4 (0.3-10.4) |
| Outpatient allograft infusion | 35 (100) |
| Admission within 100 d | 22 (63) |
| Hospital stay, median (range), d* | 4 (1-74) |
| Cause of admission*(n = 22) | |
| Neutropenic fever | 3 |
| Non-neutropenic fever | 6 |
| Central catheter–related infection | 4 |
| Serum sickness | 3 |
| Others† | 6 |
| Post-HCT cytopenias in first 100 d | |
| Patients with neutrophil nadir <0.5 × 109/L | 6 (17) |
| Patients with platelet nadir <10 × 109/L | 2 (6) |
| Patients with no blood product transfusions | 16 (46) |
| Posttransplant PRBC transfusions, median (range) | 3 (1-35) |
| CMV in first 100 d, n | |
| Reactivation (viremia only)‡ | 17 (49) |
| Organ disease | 0 (0) |
| EBV reactivation§ | 10 (29) |
| Cause of death (n = 17) | |
| Disease progression/relapse | 12 |
| Acute GVHD | 1 |
| Chronic GVHD | 1 |
| Secondary malignancy | 1 |
| Hepatitis | 1 |
| Hemorrhage | 1 |
Values are n or n (%), except as noted.
PRBC, packed red blood cell.
Among patients admitted within the first 100 d after hematopoietic cell transplantation (HCT).
Other causes of admission included one case each of syncope, appendicitis, transaminitis, delirium, vision changes, and acute GVHD.
Any CMV copy number >200/mL was treated with valganciclovir. Organ disease was proven by using biopsy results or shell-vial positive.
Epstein-Barr virus (EBV) copy number of >10 000/mL or imaging/histopathology suggestive of posttransplant lymphoproliferative disease in 2 patients was treated with 4 weekly doses of rituximab (375 mg/m2).